The DOI matches its Crossref record, with a small difference in title or year; 36 of the 36 references it cites were found in a registry or an index.
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Abstract
Background—: Despite the known association of diabetes mellitus with cardiovascular events, there are few contemporary data on the long-term outcomes from international cohorts of patients with diabetes mellitus. We sought to describe cardiovascular outcomes at 4 years and to identify predictors of these events in patients with diabetes mellitus. Methods and Results—: The Reduction of Atherothrombosis for Continued Health (REACH) registry is an international registry of patients at high risk of atherothrombosis or established atherothrombosis. Four-year event rates in patients with diabetes mellitus were determined with the corrected group prognosis method. Of the 45 227 patients in the REACH registry who had follow-up at 4 years, 43.6% (n=19 699) had diabetes mellitus at baseline. The overall risk and hazard ratio (HR) of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke were greater in patients with diabetes compared with patients without diabetes (16.5% versus 13.1%; adjusted HR, 1.27; 95% confidence interval [CI] 1.19–1.35). There was also an increase in both cardiovascular death (8.9% versus 6.0%; adjusted HR, 1.38; 95% CI, 1.26–1.52) and overall death (14.3% versus 9.9%; adjusted HR, 1.40; 95% CI, 1.30–1.51). Diabetes mellitus was associated with a 33% greater risk of hospitalization for heart failure (9.4% versus 5.9%; adjusted odds ratio, 1.33; 95% CI, 1.18–1.50). In patients with diabetes mellitus, heart failure at baseline was independently associated with cardiovascular death (adjusted HR, 2.45; 95% CI, 2.17–2.77; P <0.001) and hospitalization for heart failure (adjusted odds ratio, 4.72; 95% CI, 4.22–5.29; P <0.001). Conclusions—: Diabetes mellitus substantially increases the risk of death, ischemic events, and heart failure. Patients with both diabetes mellitus and heart failure are at particularly elevated risk of cardiovascular death, highlighting the need for additional therapies in this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [4]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [53]
In the citing paper
“Recent studies have found that rates of incident heart failure hospitalization (adjusted for age and sex) were twofold higher in people with diabetes compared with those without (5,6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-H., Stevens, G. A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60679-x · Cited by 3,568
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
Self-citationBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Self-citationA Tale of Coronary Artery Disease and Myocardial Infarction
Nabel, E. G., & Braunwald, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112570 · Cited by 1,024
Bhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.025 · Cited by 805
Self-citationBhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationDiabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Trends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010
Selvin, E., Parrinello, C. M., Sacks, D. B., & Coresh, J. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2411 · Cited by 532
Huang, E. S., Laiteerapong, N., Liu, J. Y., John, P. M., Moffet, H. H., & Karter, A. J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12956 · Cited by 501
Abbott, R. D. (1988) · JAMA · doi:10.1001/jama.260.23.3456 · Cited by 500
Ohman, E. M., Bhatt, D. L., Steg, P. G., Goto, S., Hirsch, A. T., Liau, C., Mas, J., Richard, A., Röther, J., & Wilson, P. W. F. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.11.004 · Cited by 307
Self-citationHeart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 305
Predictors of late development of heart failure in stable survivors of myocardial infarction
Lewis, E. F., Moyé, L. A., Rouleau, J. L., Sacks, F. M., Arnold, J. M. O., Warnica, J. W., Flaker, G. C., Braunwald, E., & Pfeffer, M. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)01057-x · Cited by 304
Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Self-citationMetabolic Impairment in Heart Failure
Doehner, W., Frenneaux, M. P., & Anker, S. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.083 · Cited by 241
Lincoff, A. M., Tardif, J., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B. C., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 232
Singh, M., Rihal, C. S., Gersh, B. J., Lennon, R. J., Prasad, A., Sorajja, P., Gullerud, R. E., & Holmes, D. R. (2007) · Circulation · doi:10.1161/circulationaha.106.632679 · Cited by 129
Corrected group prognostic curves and summary statistics
Chang, I.-M., Gelman, R. S., & Pagano, M. (1982) · Journal of Chronic Diseases · doi:10.1016/0021-9681(82)90019-4 · Cited by 111
The Population Burden of Heart Failure Attributable to Modifiable Risk Factors
Avery, C. L., Loehr, L. R., Baggett, C. D., Chang, P. P., Kucharska‐Newton, A., Matsushita, K., Rosamond, W. D., & HEISS, G. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.022 · Cited by 106
Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes
Bhatt, D. L., Hulot, J., Moliterno, D. J., & Harrington, R. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302737 · Cited by 96
Self-citationKrempf, M., Parhofer, K. G., Steg, P. G., Bhatt, D. L., Ohman, E. M., Röther, J., Goto, S., Pasquet, B., & Wilson, P. W. F. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.048 · Cited by 82
Self-citationProspective development and validation of a model to predict heart failure hospitalisation
Cubbon, R. M., Woolston, A., Adams, B., Gale, C. P., Gilthorpe, M. S., Baxter, P. D., Kearney, L. C., Mercer, B. N., Rajwani, A., Batin, P. D., et al. (2014) · Heart · doi:10.1136/heartjnl-2013-305294 · Cited by 52
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
Examine Investigators (2014) · Aston Publications Explorer (Aston University) · Cited by 36
Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease
Bhatt, D. L. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.018 · Cited by 28
Self-citationDo Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?
Bhatt, D. L., & Cavender, M. A. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.05.005 · Cited by 26
Self-citationUdell, J. A., Scirica, B. M., Braunwald, E., Raz, I., Steg, P. G., Davidson, J. A., Hirshberg, B., & Bhatt, D. L. (2012) · Clinical Cardiology · doi:10.1002/clc.22032 · Cited by 23
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1001/jama.1988.03410230074031 · DOI
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Metadata
- Authors
- Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- From TIMI Study Group, Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (M.A.C., J.K., K.I., D.L.B.); French Alliance for Cardiovascular Clinical Trials, Département Hospitalo-Universitaire, Fibrosis, Inflammation, Remodeling, Université Paris-Diderot, Sorbonne Paris-Cité, Laboratory of Vascular Translational Science, INSERM U-1148, Hôpital Bichat, Hopitaux Universitaires Paris-Nord Val de Seine, Assistance Publique–Hôpitaux de Paris, Paris, France (P.G.S.);...
- ORCID
- Venue
- Circulation
- Published
- 2015-09-08
- Volume
- 132
- Issue
- 10
- Pages
- 923-931
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2154038775
- Cited by
- 501
- References
- 36
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 43 · 2023: 51 · 2022: 75 · 2021: 61 · 2020: 80 · 2019: 56 · 2018: 49 · 2017: 34 · 2016: 17 · 2015: 4
- FWCI
- 30.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- diabetes mellitus, heart failure hospitalization, cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, heart failure with reduced ejection fraction, risk factors, REACH registry, atherothrombosis, long-term outcomes, comorbidity burden, mortality risk stratification, heart failure with preserved ejection fraction
- MeSH terms
- Aged, Diabetes Mellitus, Female, Follow-Up Studies, Health Status, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Mortality, Prospective Studies, Registries, Thrombosis, Time Factors, Cohort Studies, Treatment Outcome, Internationality, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
